SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis.
作者信息
Tuncay Gülseren, Bostan Ozge Can, Damadoglu Ebru, Karakaya Gül, Kalyoncu Ali Fuat
机构信息
Division of Allergy and Clinical Immunology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Division of Allergy and Clinical Immunology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
出版信息
Ann Allergy Asthma Immunol. 2022 Jun;128(6):733-734. doi: 10.1016/j.anai.2022.02.026. Epub 2022 Mar 4.
Abstract
摘要
相似文献
1
SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis.
Ann Allergy Asthma Immunol. 2022 Jun;128(6):733-734. doi: 10.1016/j.anai.2022.02.026. Epub 2022 Mar 4.
2
Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?
J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):193-195. doi: 10.18176/jiaci.0680. Epub 2021 Feb 12.
3
Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome.
J Allergy Clin Immunol Pract. 2021 Aug;9(8):3198-3199. doi: 10.1016/j.jaip.2021.05.010. Epub 2021 May 24.
4
COVID-19 infection and vaccination in 92 pediatric patients with cutaneous mastocytosis: A retrospective, cross-sectional study.
Pediatr Dermatol. 2024 May-Jun;41(3):458-460. doi: 10.1111/pde.15551. Epub 2024 Feb 2.
5
mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.
J Allergy Clin Immunol. 2021 Mar;147(3):877-878. doi: 10.1016/j.jaci.2021.01.004. Epub 2021 Jan 19.
6
SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies.
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115565. doi: 10.1016/j.diagmicrobio.2021.115565. Epub 2021 Oct 2.
7
COVID-19 vaccines and decreased transmission of SARS-CoV-2.
Inflammopharmacology. 2021 Oct;29(5):1357-1360. doi: 10.1007/s10787-021-00847-2. Epub 2021 Jul 19.
8
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2139-2144. doi: 10.1016/j.jaip.2021.03.041. Epub 2021 Apr 5.
9
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001553.
10
COVID-19 vaccination is highly effective to prevent SARS-CoV-2 circulation.
J Infect Public Health. 2022 Apr;15(4):395-396. doi: 10.1016/j.jiph.2022.03.006. Epub 2022 Mar 12.
引用本文的文献
1
Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy.
Vaccines (Basel). 2024 Feb 16;12(2):202. doi: 10.3390/vaccines12020202.
2
Latent Mastocytosis Triggered by COVID-19 Vaccination: A Case Report.
Endocr Metab Immune Disord Drug Targets. 2024;24(4):495-498. doi: 10.2174/0118715303241179230927105454.
3
Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population.
Eur J Haematol. 2023 Jan;110(1):67-76. doi: 10.1111/ejh.13875. Epub 2022 Oct 17.
Zotero 插件